Sumitomo Pharma Co., Ltd.: Pulmonary Disease, Chronic Obstructive trials

The registry lists 20 Pulmonary Disease, Chronic Obstructive studies with Sumitomo Pharma Co., Ltd. as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 1Phase 2 6Phase 3 9Phase 4 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.CompletedNCT04155047Phase 4Results posted
• Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02951312Phase 2Results posted
• Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02948582Phase 2Results posted
• Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT02512302Phase 1Results posted
• Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)CompletedNCT02347774Phase 3Results posted
• A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPDCompletedNCT02276222Phase 3Results posted
• A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) SubjectsTerminatedNCT02275481Phase 4Results posted
• A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01706536Phase 2Results posted
• Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 StudyCompletedNCT01426009Phase 2Results posted
• Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) SubjectsCompletedNCT00909779Phase 3Results posted
• Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPDCompletedNCT00571428Phase 4Results posted
• Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00424528Phase 4Results posted
• Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT00250679Phase 3Results posted
• A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00691405Phase 2
• A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00685841Phase 3
• Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00685529Phase 2
• Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00665600Phase 3
• Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPDCompletedNCT00583986Phase 3
• To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPDCompletedNCT00064415Phase 3
• Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPDCompletedNCT00064402Phase 3